August 7, 2026 - A reunion with a long-standing companion: Saxon State Parliament member Thomas Schmidt visited our Radiopharmacy to learn about its development since its inauguration in 2020. The discussions focused on the future of radiopharmacy and nuclear medicine as well as the European framework for innovative diagnostic and therapeutic approaches.

April 27, 2026 - ROTOP Pharmaka GmbH today announced that it has received the building permit for a new radiopharmaceutical manufacturing facility in Dresden. The approval represents a major step in the company’s growth strategy and further strengthens its position as a leading radiopharmaceutical partner in Europe.

March 13, 2026 - We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP. Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations.

January 9, 2026 - ROTOP Pharmaka welcomed Saxony’s State Minister Dirk Panter during the region’s Radiopharmacy Theme Day. The exchange highlighted the importance of modern radiopharmacy for cancer care as well as ROTOP’s contribution through diagnostics, ready to use patient doses, and CDMO services, with a particular focus on theranostic concepts.

August 15, 2025 - We are delighted to be featured in the latest issue of VentureCapital Magazine, which spotlights the Dresden region as a high-performance hub for key players and innovators in radiopharmaceutical innovation. ROTOP Pharmaka is recognized as a leading manufacturer of radiopharmaceuticals, including an iodine-123 compound used in Parkinson’s diagnostics. The article also emphasizes the strong network we are part of – combining research collaborations, advanced manufacturing, and the development of innovative theranostic solutions.

August 14, 2025 - We are delighted to announce that RoTecPSMA® has received marketing authorization in Switzerland, marking another important milestone in the European rollout of this innovative diagnostic solution. This approval, achieved in close collaboration with our trusted partner and marketing authorization holder medeo AG, paves the way for Swiss patients to benefit from our PSMA SPECT tracer.

July 18. 2025 - Team ROTOP - Jens Junker, Felix Roschke, Thomas Gottlieb and Tanmaya Joshi - just returned from SNMMI 2025 in New Orleans. This year, the event brought together nearly 8,000 professionals from across the nuclear medicine and radiopharmaceutical world.

May 14, 2025 - We are thrilled to announce that RoTecPSMA® has been approved in the United Kingdom! RoTecPSMA® is a technetium-99m cold kit for SPECT imaging of prostate cancer patients and the first PSMA-SPECT tracer approved in a European country. It marks a significant step forward in closing a gap in patient care, making advanced diagnostics more accessible for those affected by prostate cancer.

January 20, 2025 - ROTOP Pharmaka GmbH is pleased to announce new investments secured from GENUI & SHS Capital along with the appointment of Andrew Varghese as its new President of ROTOP USA. With the new investments ROTOP secured from GENUI & SHS Capital, ROTOP is further positioned to expand the footprint and be a significant player in the CDMO space to provide clinical and commercial batch volumes both in cold and hot products.

January 16, 2025 - Saxon radiopharmacy network nukliD® strengthens international visibility. Today, Thursday 16 January 2025, leading German and international players in the field of radiopharmacy from Saxony agree to intensify their collaboration. The aim of the partners from the fields of research, industry and cluster management is to develop radiopharmacy in Saxony into a centre of innovation and expertise in this pioneering field and thus make it more visible internationally. To this end, have joined forces under the name Radiopharmacy Cluster Dresden - nukliD®.